News about "Financial Results"

Gland Pharma Reports Revenue of INR 14,058 Million in Q2FY25

Gland Pharma has reported a consolidated revenue of INR 14,058 million for Q2 FY25, marking a 2 percent increase compared to INR 13,734 million in Q2 FY24.

Financial Results | 05/11/2024 | By Aishwarya

Indegene Achieves Revenue of INR 6,868 Million in Q2FY25

In the second quarter of the financial year 2025, Indegene achieved revenue from operations totaling INR 6,868 million, marking an 8.0 percent Year-over-Year (YoY) growth compared to the same period in the previous year.

Financial Results | 29/10/2024 | By Aishwarya |  116

Strides Pharma Shows Strong Q1FY25 Results with 16.7 Percent of Revenue Growth

Strides Pharma Science Ltd. has announced its consolidated financial results for the quarter (Q1FY25).

Financial Results | 29/07/2024 | By Aishwarya |  105

Gland Pharma Reports Remarkable Q4FY24 and FY24 Financial Performance

Gland Pharma Ltd. has announced its financial results for the fourth quarter (Q4FY24) and full year (FY24) ended on Mar 31, 2024.

Financial Results | 23/05/2024 | By Aishwarya |  152

Strides Announces Best-Ever Financial Results for FY24

Strides Pharma Science Ltd. has published its consolidated financial results for the quarter (Q4FY24) and full year (FY24) ended March 31, 2024.

Financial Results | 23/05/2024 | By Aishwarya |  433

Granules India Records 2 Percent Growth in Revenue from Operations in Q4FY24

Granules India Ltd., has announced its financial results for the quarter and financial year ended March 31, 2024.

Financial Results | 17/05/2024 | By Aishwarya |  158

Hikal Limited Shows Resilient Performance Amid Industry Headwinds

Hikal’s Panolisite undergone US FDA audit which was concluded with ‘Zero’ 483 observations. US FDA approval is in line with de-risking strategy for additional API site to service our global customer base.

Financial Results | 10/08/2023 | By Manvi |  340

Granules India Q1FY24 Revenue from Operations at INR 9855 mn down 3 Percent YoY

ROCE stood at 9.4 percent and net debt stood at INR 8,569 mn

Financial Results | 10/08/2023 | By Manvi |  281

IOL Chemicals and Pharmaceuticals Net Profit Grows 32 Percent YoY

The total income for Q1 FY24 stood at INR 570 crore at the same level of INR 570 crore YoY. EBITDA for Q1 FY24 was INR 80 crore as compared to INR 61 crore YoY.

Financial Results | 10/08/2023 | By Manvi |  362

JB Pharma Records Revenue Growth of 14 Percent to INR 896 Crores in Q1 FY24

For the first quarter of FY24 ended June 30, 2023, JB Pharma recorded revenue of INR 896 crores growing 14 percent from INR 785 crores in the corresponding quarter.

Financial Results | 09/08/2023 | By Manvi |  505